Related coverage linked through entity extraction aliases.
Feb 25, 2025
Monthly patent reviews from April through December 2025 highlight notable drug discovery IP disclosures across targeted protein degradation, small molecule modulators, and emerging therapeutic targets in oncology, immunology, and neurology.
Dec 12, 2025
Eli Lilly reported positive Phase 3 results for retatrutide showing up to 71.2 lbs average weight loss, while stockpiling $1.5 billion of oral drug orforglipron ahead of anticipated FDA approval in April 2026.
Feb 11, 2026
The FDA announced a full reassessment of butylated hydroxyanisole (BHA), a chemical preservative used in packaged foods, to determine if it remains safe based on current science. The review follows decades of concerns about BHA being listed as "reasonably anticipated to be a human carcinogen."
Feb 13, 2026
The global epigenetics drugs and diagnostic technologies market is projected to reach USD 79.03 billion by 2035, while the genomics in cancer care market is expected to hit USD 108.69 billion, driven by precision medicine advances and AI integration.
Feb 13, 2026
The global genomics in cancer care market is projected to grow from $24.39 billion in 2025 to $108.69 billion by 2035, driven by rising cancer incidence, personalized medicine adoption, and next-generation sequencing advances.
Feb 13, 2026
Isomorphic Labs introduced IsoDDE, a drug discovery engine that outperforms AlphaFold 3 by a factor of two in prediction accuracy. Google also updated Gemini 3 Deep Think, which now outperforms competing models in complex scientific tasks.
Feb 13, 2026
Dr Reddy's and Biocon plan to launch generic versions of Novo Nordisk's weight-loss drugs at up to 60% below branded prices as semaglutide patents expire, targeting a global market projected to reach $150 billion by the early 2030s.
